Seth Harmon
Chief Financial Officer at Viridian Therapeutics, Inc.\DE (VRDN) since September 2023
Seth Harmon has filed 6 insider reports with the SEC since September 2023, as chief Financial Officer at Viridian Therapeutics, Inc.\DE (VRDN). The latest filing, on March 9, 2026, reports shares withheld for taxes or exercise price at Viridian Therapeutics, Inc.\DE (VRDN).
- Filings
- 6
- Companies
- 1
- Bought on market
- None
- Sold on market
- None
Companies where Seth Harmon is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Financial Officersince September 2023 | 7,850 | $30.87 | Mar 9, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Mar 3, 2026VRDNAmendment: Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,031 shares, decreasing direct ownership by 21% to 7,850 unitsForm 4Shares withheld for taxes or exercise price
- Mar 3, 2026VRDNChief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 unitsForm 4Grant or awardShares withheld for taxes or exercise priceExercise or conversion of a derivative
- Mar 5, 2026VRDNAmendment: SEC Form 4 filed by Chief Financial Officer Harmon SethForm 4
- Mar 3, 2025VRDNSEC Form 4 filed by Chief Financial Officer Harmon SethForm 4Grant or award
- Nov 10, 2023VRDNSEC Form 4 filed by Harmon SethForm 4Grant or award
- Sep 12, 2023VRDNSeth Harmon became an insiderForm 3New insider
Compare Seth Harmon with
- Seth Harmon vs Jennifer Tousignant1 shared
- Seth Harmon vs Radhika Tripuraneni1 shared
- Seth Harmon vs Arlene Morris1 shared
- Seth Harmon vs Sarah Gheuens1 shared
- Seth Harmon vs Tomas Kiselak1 shared
- Seth Harmon vs Jeffrey Robert Ajer1 shared
Other insiders at the same companies
- Jennifer TousignantVRDN
- Radhika TripuraneniVRDN
- Sarah GheuensVRDN
- Arlene MorrisVRDN
- Tomas KiselakVRDN
- Christopher W. CainVRDN
- Jeffrey Robert AjerVRDN
- Jennifer K. MosesVRDN
- Fairmount Funds Management LLCVRDN
- Thomas W. BeethamVRDN
- Stephen F. MahoneyVRDN
Questions about Seth Harmon
- What is Seth Harmon's role at Viridian Therapeutics, Inc.\DE?
- Seth Harmon reports to the SEC as chief Financial Officer at Viridian Therapeutics, Inc.\DE (VRDN), according to the latest filing on March 9, 2026.
- How many shares does Seth Harmon own?
- After the latest filing that states it, Seth Harmon directly owned 7,850 shares of Viridian Therapeutics, Inc.\DE (VRDN). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Seth Harmon bought or sold stock recently?
- No open-market purchases or sales by Seth Harmon are on file. The filings report shares withheld for taxes or exercise price, grant or award and exercise or conversion of a derivative.
- How do I get alerts when Seth Harmon files?
- Follow Seth Harmon on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Seth Harmon (SEC CIK 0001993300). Totals count each trade once, skipping amendments whose original is on file, from Sep 19, 2023 on. View on SEC EDGAR